We developed European guidelines to optimise phenylketonuria (PKU) care. To develop the guidelines, we did a literature search, critical appraisal, and evidence grading according to the Scottish Intercollegiate Guidelines Network method. We used the Delphi method when little or no evidence was available. From the 70 recommendations formulated, in this Review we describe ten that we deem as having the highest priority. Diet is the cornerstone of treatment, although some patients can benefi t from tetrahydrobiopterin (BH4). 
Introduction
Phenylketonuria (PKU) is a rare autosomal recessive inborn error of phenylalanine metabolism with an estimated frequency in Europe of 1 in 10 000 newborn babies (panels 1 and 2). 1 Defi ciency of the hepatic-based enzyme phenylalanine hydroxylase (PAH) results in a complete or partial inability to convert phenylalanine (from the diet or derived from catabolism of proteins in the body) to tyrosine (fi gure 1), 2 which can lead to high blood phenylalanine concentrations that cross the bloodbrain barrier causing detrimental eff ects on brain development and function. Available treatments aim to decrease the blood phenylalanine concentration, which is considered the surrogate marker for brain phenylalanine concentrations. Nevertheless, the precise pathophysiology of PKU remains unclear (fi gure 2). 3 Clinically, untreated PKU is characterised by irreversible intellectual disability, microcephaly, seizures, aberrant behaviour, psychiatric symptoms, motor disturbances, and eczematous rash. When diagnosed by newborn screening and treated immediately, patients essentially show normal development, although neuropsychological defi cits and behavioural and social issues can occur. 2, 5 Dietary treatment consists of a low-phenylalanine diet, restrictive in natural protein combined with phenylalanine-free L-aminoacid supplements and low protein foods. Some patients with PKU respond to tetrahydrobiopterin (BH4), a naturally occurring essential cofactor for PAH that acts as a pharmaceutical chaperone (prescribed as sapropterin dihydrochloride), decreases blood phenylalanine concentrations and increases dietary phenylalanine tolerance. 2 In some (mainly nonEuropean) countries, casein glyco macropeptide or large neutral aminoacids are used for treatment, but both 2 PKU is caused by mutations in the gene encoding phenylalanine hydroxylase (PAH). The PAH gene is located on chromosome 12 (region q22-24.1) consisting of 13 exons and 12 introns, in total covering 100 kb of genetic data. More than 950 mutations in the gene encoding PAH (BIOPKU database) are known to be associated with PAH defi ciency. Most of the mutations are missense, usually resulting in protein misfolding or impairment of catalytic functions. The prevalence of PKU shows considerable geographic variation; in Europe it occurs in one in 10 000 newborn babies, with a higher rate in some countries, such as Ireland and Turkey, but a very low rate in Finland. 2 Phenylalanine is hydroxylated by PAH, necessitating tetrahydrobiopterin (BH4) as a cofactor, with iron and oxygen. The structure of PAH is a tetramer. During the hydroxylation of phenylalanine, BH4 is oxidised to a 4a-hydroxy intermediate, which is subsequently regenerated to BH4 by the enzymes carbinolamie-4a-dehydratase and dihydropteridine reductase. BH4 is synthesised from guanosine triphosphate (GTP) by three additional enzymes: GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, and sepiapterin reductase. Variants in the genes encoding the enzymes involved in BH4 metabolism result in BH4 defi ciency, mostly treated with BH4 and neurotransmitter precursors. Some patients with PAH defi ciency also respond to BH4. This response is referred to as BH4 responsiveness.
Genetics of PKU

Phenylalanine hydroxylase
Review safety and effi cacy of these treatment strategies need further study. 2 PKU management diff ers across Europe, with various local and national guidelines. A need exists for more standardised management tailored for optimal outcomes. 6, 7 The development of these European guidelines was driven both by health professionals and the patient organisation European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria (ESPKU). [7] [8] [9] Generally, guidelines should result in measurable improve ments in patient care, 10, 11 consistent, high-quality treatment without inequity, and awareness of rare diseases. 12 Here we report on the development of European PKU guidelines by 19 European PKU experts, and we highlight ten clinical recommendations (out of a total of 70) that we deem as having the highest priority for implementation. The key recommendations were based on the best available evidence for management of PKU that would achieve optimal clinical and neuropsychological outcomes without overtreatment and unnecessary costs.
Guideline development
The scientifi c advisory committee of the ESPKU was tasked with organising a group of European PKU experts. 19 health professionals were invited on the basis of their experience and expertise rather than nationality; one of them declined and one resigned for personal reasons. The 17 professionals included the following: paediatric and adult metabolic physicians, a paediatric neurologist, a biochemist, metabolic dietitians, neuropsychologists, and psychologists. They were divided into fi ve working groups on (1) nutritional treatment and biochemical or nutritional follow-up (Working Group A); (2) neurocognitive outcomes including imaging (Working Group B); (3) psychosocial outcome, and adherence (Working Group C); (4) adult and maternal PKU, and late diagnosis of PKU and untreated PKU (Working Group D); and (5) diagnosis of PKU including treatment initiation and drugs in PKU (Working Group E). The working groups were supported by a project assistant and guidelines leader. We consulted an obstetrician for maternal PKU. We developed the guidelines between October, 2012, and December, 2015.
We developed the guidelines with the Appraisal of Guidelines, Research, and Evaluation in Europe method. We did the literature search, critical appraisal, and evidence grading according to the Scottish Intercollegiate Guidelines Network (SIGN) method (version 2011) using eight levels of evidence being transferred into grades of recommendations (from A [highest] to D [lowest] , with an extra recommendation for so-called good practice points that are not based on any evidence).
All working groups defi ned key questions, after which they searched the published work for relevant papers with the help of the project assistant. All working groups and plenary sessions, to discuss as adequately as possible the statements without enough evidence, 
Executive functioning
Executive functioning describes cognitive processes that regulate behaviour; examples are inhibitory control, working memory, and cognitive fl exibility.
High-risk pregnancy
A pregnancy that threatens the health or life of the mother or her fetus.
Hyperphenylalaninaemia
Any blood phenylalanine concentration more than 120 μmol/L.
Late treated or untreated adults
Late diagnosis refers to children diagnosed between ages 3 months and 7 years (≥3 months to <7 years). Untreated refers to patients who are untreated at age 7 years or older.
Maternal PKU syndrome
The teratogenic eff ects of elevated maternal phenylalanine levels during pregnancy to the fetus.
Phenylalanine tolerance
The amount of phenylalanine (mg/kg per day or mg per day) that maintains plasma phenylalanine concentrations within the target range. This amount might also be described as natural protein tolerance expressed as g per day, taking a phenylalanine content in natural protein as 50 mg of phenylalanine per gram of natural protein.
Protein requirements
The lowest level of dietary protein intake that will balance the loss of nitrogen from the body, and thus maintain the body protein mass in a person at energy balance with modest levels of physical activity.
Protein substitutes (phenylalanine-free L-aminoacid supplements and low phenylalanine glycomacropeptide protein) Protein replacements or substitutes are essential in treatment of PKU to prevent protein defi ciency and optimise metabolic control. Protein substitutes are mainly sourced from phenylalanine-free L-aminoacid supplements and less commonly from low phenylalanine glycomacropeptide.
BH4
Cofactor of phenylalanine hydroxylase. BH4 also acts as a chaperone protein in some patients who are defi cient in phenylalanine hydroxylase. BH4 is a cofactor of tyrosine and tryptophan hydroxylase and has a role in the conversion of L-arginine to nitric oxide by nitric oxide synthases.
BH4 defi ciencies
Defects in BH4 metabolism (either synthesis or turnover) result in a defi ciency of BH4. These include three known defects for synthesis and two for regeneration (see also phenylalanine hydroxylase in panel 1).
Potential BH4 responsiveness
More than 30% reduction in blood phenylalanine in a BH4 loading test or two BH4-responsive mutations. BH4 responsiveness should be proven in a treatment trial adjusting the BH4 dosing, natural protein intake, and phenylalanine-free L-aminoacid supplement.
BH4 responsiveness
In this Review we defi ned BH4 responsiveness as an increase of 100% or more in natural protein or improved biochemical control (>75% of phenylalanine levels in target range), or both, on a dose of BH4 that ranges between 1-20 mg/kg bodyweight (with a maximum dose of 1000 or 1400 mg per day in some countries).
For more on the BIOPKU database see http://www.biopku.org/home/ pah.asp were facilitated by the guidelines leader or project assistant, or both. We sent a concept of the full guidelines worldwide to 14 external consultants (physicians and dietitians or nutritionists) and the board of the ESPKU. Further data about the process (including the questions for each of the key recommendations reached) are shown in the appendix.
Guidelines Overview
The main topics of these guidelines are (1) diagnosis, treatment initiation, and treatment duration; (2) treatment targets; (3) practical issues in dietary and BH4 treatment; (4) follow-up; and (5) special conditions (maternal PKU; late PKU diagnosis and untreated PKU). In the fi nal section, we discuss the future goals of PKU management. Panel 3 lists the ten key statements arising from these main topics. Some aspects of this Review are lacking a discussion in depth in part related to the length of the paper but also in part related to a lack of evidence. Where this is the case it is stated.
Diagnosis and treatment initiation and duration
Most of the statements on diagnosis and classifi cation are experience-based rather than evidence-based.
2 PAH defi ciency is usually classifi ed as mild, moderate, or severe (also referred to as classic) PKU. This classifi cation is commonly based on the highest untreated blood phenylalanine concentration following a clinical diagnosis or at newborn screening. However, blood samples for newborn screening might be collected before infants have achieved their peak phenylalanine concentration without treatment. Since this sample collection time limits the use of the traditional classifi cation for severity, a new classifi cation is proposed on the basis of whether patients with PAH defi ciency-to maintain blood phenylalanine concentrations in the recommended range-do not need treatment, or require dietary intervention, or BH4, or both.
Newborn screening for PKU meets all accepted screening criteria including cost-benefi t ratio. 13 Therefore, newborn screening for PKU should be done in every European country. This screening not only needs a robust infrastructure in which blood is taken from all newborn babies within a few days of birth, but also a well equipped laboratory that can manage and assess bloodspots effi ciently. Low-income countries might consider using newborn screening laboratory facilities of another country as a possible option.
In any child referred for hyper phenylalaninaemia, BH4 defi ciencies and liver disease should be excluded, as these require other treatment strategies. Before starting treatment or doing a BH4 challenge, samples for pterins in blood and urine and dihydropteridine reductase activity in dried blood spots are taken. Additionally, a 24 h BH4 loading test might be useful, especially if time until receipt of laboratory results of pterins and dihydropteridine reductase activity is an issue. BH4 defi ciencies should be considered in any child with neurological problems of unknown origin with even only slightly increased blood phenylalanine concentrations.
In patients with PKU, every 4 week delay in starting treatment results in a decline of approximately four intelligence quotient (IQ) points, 14 which underscores the knowledge that neurological damage starts early after birth. Therefore, the organisation of newborn screening and referral to PKU centres is strongly advocated so that treatment is started no later than 10 days of age.
A clear consensus exists that patients with untreated blood phenylalanine concentrations of less than 360 μmol/L do not require treatment and that treatment is required in those with phenylalanine concentrations of more than 600 μmol/L. The necessity of treatment for untreated phenylalanine concentrations between 360 μmol/L and 600 μmol/L is less clear; 15, 16 only Weglage and colleagues 17 have adequately studied patients with untreated phenylalanine concentrations within this range and suggested it was safe. However, in that study only seven of the 31 patients had an untreated phenylalanine concentration of more than 500 μmol/L, and on such evidence we consider it inappropriate to recommend that untreated phenylalanine concentrations of 360-600 μmol/L are safe. 17 Therefore, we advise treatment for any child with untreated phenylalanine concentrations of more than 360 μmol/L. This advice is not based on conclusive evidence and further data are still required for a defi nitive recommendation.
With regards to the duration of treatment, we advise treatment until age 12 years in individuals with untreated phenylalanine concentrations between 360 μmol/L and Review 600 μmol/L, providing blood phenylalanine remains less than 600 μmol/L without treatment afterwards. We suggest this duration because of scarce and inconsistent evidence and the necessity for good metabolic control to retain cognitive function, especially during the fi rst 12 years of life. 18, 19 In untreated women with phenylalanine concentrations of more than 360 μmol/L, treatment is also required preconception and during pregnancy with the aim of reducing phenylalanine concentrations to less than 360 μmol/L.
In patients with untreated phenylalanine concentrations of more than 600 μmol/L, it is clearly unsafe to discontinue treatment before reaching adulthood (age 18 years), [20] [21] [22] [23] but the need to continue treatment during adulthood has been challenged. Evidence from the results of studies summarised in a systematic review show that in adults treated early (with treatment continued or discontinued) for PKU (usually >600 μmol/L), significant suboptimal outcomes occur compared with healthy individuals, including defi cits in executive function, attention problems, decreased verbal memory, expressive naming and verbal fl uency, mood, and social and emotional diffi culties. 4 Whether these suboptimal outcomes are because of suboptimal treatment during adulthood, adolescence, or even before is unclear. Adults treated early (treatment was both continued and discontinued) for PKU usually show a clear association between concurrent blood phenylalanine concentrations and certain aspects of brain function, brain metabolism, and diff erences in myelination, as summarised by van Spronsen and colleagues. 24 Adult patients with PKU, who are no longer on a phenylalanine restricted diet, can experience neurological complications 25 and vision loss 26, 27 that can improve or even reverse after reinstitution of treatment. [25] [26] [27] In adults continuing treatment for PKU, results of health-related quality of life surveys suggest that this quality of life is normal, with an improvement of healthrelated quality of life in some patients who had returned to a low phenylalanine diet having discontinued PKU treatment. 28, 29 However, non-PKU generic health-related quality of life questionnaires are insensitive to the subtle negative eff ects of PKU, which has led to the development of a validated PKU-specifi c questionnaire (PKU-QOL). 30, 31 On the basis of these data, we advise treatment for life for patients with untreated phenylalanine concentrations of more than 600 μmol/L, even though it is acknowledged that dietary management is associated with a substantial patient burden.
Treatment targets
Blood phenylalanine is the primary marker for guiding available treatments. 18, 19, 32 Table 1 lists the studies that were included through use of the SIGN method to achieve the highest level of evidence available for the statements that describe age-related target ranges. For children up to the age of 12 years, the results of meta-analyses by Albrecht and colleagues 32 and Waisbren and colleagues 18 suggested safe upper target blood phenylalanine concentrations of 320 μmol/L 32 and 420 μmol/L, 18 and Fonnesbeck and colleagues 19 indicated that a mean concentration of 400 μmol/L was associated with an increased risk of an IQ less than 85. Some evidence also exists that shows more favourable outcomes when the mean blood phenylalanine concentrations are less than 240 μmol/L rather than 360 μmol/L (mean age <12 years). 41 Jahja and colleagues 41 reported a better neuropsychological task performance by patients with PKU when blood phenylalanine concentrations were less than 240 μmol/L than patients with concentrations between 240 μmol/L and 360 μmol/L (mean age <12 years); however, despite being statistically signifi cant, diff erences of inhibitory control and cognitive fl exibility, and motor control were not clinically signifi cant. Therefore, in view of the overall available evidence, we advise 360 μmol/L as the upper target phenylalanine blood concentration for the fi rst 12 years of life. Data about adolescents and adults are scarce, necessitating further data collection within long-term international collaborative studies. Using the data shown in table 1, we advise an upper target phenylalanine blood concentration of 600 μmol/L for all individuals older than 12 years. This statement is diff erent when compared to the upper target phenylalanine concentration of 360 μmol/L for adults with PKU, as advised by the American College of Genetics and Genomics. 45 The upper target of 360 μmol/L is based on The grades range from ü (no possibility to assess the level of evidence because of a lack of any published work on this issue) to as high as B. The key recommendations were either based on evidence (if level of evidence was A or B using the SIGN method) or by consensus (using the Delphi method) if the level of evidence was C or D, or the so-called good practice points that are not based on any evidence if the level was ü.
Statement 1
Grade of recommendation: ü
To maintain blood phenylalanine concentrations in the recommended range, patients with phenylalanine hydroxylase (PAH) defi ciency can be classifi ed as either not requiring treatment, or requiring diet or tetrahydrobiopterin (BH4), or both.
Statement 2
Grade of recommendation*: C In the diff erential diagnosis of hyperphenylalaninaemia, of any degree, BH4 defi ciencies should be excluded by measurement of pterins in blood or urine and dihydropteridine reductase activity in dried blood spot.
Statement 3 Grade of recommendation: D/C
Patients with untreated blood phenylalanine concentrations less than 360 μmol/L do not require treatment. Patients with untreated blood phenylalanine levels more than 360 μmol/L should be treated. Patients with untreated phenylalanine levels between 360 μmol/L and 600 μmol/L should be treated until the age of 12 years. Patients with untreated phenylalanine levels more than 600 μmol/L should be treated for life.
Statement 4
Grade of recommendation: C All adults with PKU should have life-long, systematic follow-up in specialised metabolic centres, because of specifi c risks that might occur during adulthood.
Statement 5 Grade of recommendation: B
In treated patients with PKU up to the age of 12 years, target phenylalanine concentrations should be 120-360 μmol/L.
Statement 6
Grade of recommendation: D In treated patients with PKU aged 12 years or older, the target phenylalanine concentrations should be 120-600 μmol/L.
Statement 7
Grade of recommendation: B In pregnant patients treated for PKU the target phenylalanine concetrations should be 120-360 μmol/L.
Statement 8 Grade of recommendation: B
Women with untreated blood phenylalanine concentrations less than 360 μmol/L do not require treatment to lower blood phenylalanine before or during pregnancy.
Statement 9
Grade of recommendation: C An annual nutritional review is required for any patient who is on a prescribed low phenylalanine diet or is self-restricting high protein foods. Such review must include a clinical examination including the anthropometric parameters (weight, height, BMI). We also recommended that plasma aminoacids, plasma homocysteine or methylmalonic acid, haemoglobin, mean corpuscular volume, and ferritin are measured. All other micronutrients (vitamins and minerals including calcium, zinc, selenium) or hormones (parathyroid hormone) can be considered if clinically indicated.
Statement 10
In patients younger than 12 years, when more than 50% of the phenylalanine concentrations are out of target range over a period of 6 months, consider: (1) increased frequency of blood phenylalanine monitoring and outpatient visits and re-education, (2) psychology consultation or social worker intervention, and (3) hospital admission. When around 100% of blood phenylalanine concentrations are out of target range over a period of 6 months and there are other signs of failure of adherence, such as lack of cooperation, clinic non-attendance, or unresolved issues outside PKU consider consultation with social services and child safeguarding measures.
*Level of evidence is chosen as C because of the high number of data notwithstanding that most included papers are of descriptive nature.
Review a meta-analysis with three starting conditions: measures of cognitive outcomes other than IQ are either used non-uniformly across studies or are too diffi cult to combine; IQ variation is not an important component of variation of bias; and the eff ect of historical (lifetime) and momentary phenylalanine concentrations after 6 years of age is seen as one factor only. 19 We acknowledge the importance of this meta-analysis, 19 and think that the bias due to variation in IQ measures and variation of individual IQ over time should not be underestimated. Additionally, the eff ect of the metabolic control on adult IQ as a measure of neurocognitive outcome should not be overestimated, and in adulthood, the target phenylalanine concentration should be decided by the eff ect of phenylalanine concentrations in adult age.
As the absolute phenylalanine concentration is the most crucial factor in directing treatment, phenylalanine measurements should be robust. The accuracy of aminoacid analysers, high-performance liquid chromatography, and tandem mass spectrometry is well established, but phenylalanine concentrations from dried blood spots are 8-26% lower than venous blood 17 Bick et al (1993), 33 Kono et al (2005), 34 Cleary et al (1994), 35 samples. [46] [47] [48] Data from studies investigating neurocognitive outcomes are largely based on plasma phenylalanine concentrations, whereas routine practice is dried blood spots measurements. The guideline statements here on phenylalanine targets present the upper target phenylalanine concentrations, whereas the published work discusses means or medians. Consequently, the guideline statements are stricter than study fi ndings. However, this diff erence might also compensate for other factors, such as dried blood spots instead of plasma phenylalanine concentrations, and not testing blood phenylalanine after an overnight fast, which is usually the highest point in 24 h. 49, 50 We advise that blood phenylalanine samples are taken at the same time of day and under the same nutritional conditions in each individual patient.
Other markers, such as the phenylalanine-to-tyrosine ratio or the variation in the phenylalanine concentration, could be of additional value, 41,51-55 but any advantage off ered in addition to blood phenylalanine measure ments still remains to be determined, particularly as tyrosine concentrations vary considerably throughout 24 h.
49,56
Practical issues in dietary and BH4 treatment
Dietary phenylalanine restriction is the mainstay of treatment. This treatment consists of three parts: natural protein restriction using individual phenylalanine tolerance, 57 phenylalanine-free L-aminoacid supplements (usually with added vitamins and minerals) to meet protein and non-protein requirements, and low protein food to meet energy requirements. Although we have longstanding experience with dietary treatment, it is only since the 2008 introduction of sapropterin dihydrochloride that more of our treatment is evidencebased rather than experience-based, but important evidence gaps still exist in several areas. Patients with the most severe PAH defi ciency usually tolerate a daily intake of less than 350 mg phenylalanine, and therefore the quality of aminoacid supplements is important. Total protein intake should supply the age-related safe levels of protein intake (FAO/WHO/UNU 2007) with an additional 40% of L-aminoacids, given as natural protein or supplements according to FAO/WHO/UNU, using ideal bodyweight to calculate the dose (
[(ideal bodyweight [kg] × 0·8) -intake of natural protein (g)] × 1·4 = dose [g]).
This calculation encompasses an additional 20% of L-aminoacids to compensate for the so-called digestible indispensable aminoacid score and a further 20% of L-aminoacids to optimise the eff ect of L-aminoacids on blood phenylalanine control. If inadequate doses of L-aminoacids are given, these aminoacids become ratelimiting for protein synthesis, and protein metabolism becomes catabolism. In net protein catabolism, phenylalanine will not only remain unused for protein synthesis, but will also be released, and the concentration will increase. Therefore, giving L-aminoacids decreases the blood phenylalanine concentration.
Aminoacid supplements can cause gastrointestinal upset (abdominal pain, diarrhoea, and constipation) in young children. 58 In adult patients, life-long and higher intake of aminoacid supplements has been linked to proteinuria and decreased glomerular fi ltration rate. 59 Aminoacid supplements should be evenly administered, Review at least three times throughout the day, to minimise fl uctuations in blood phenylalanine variability. 50 Low protein foods should contain 50 mg of phenylalanine or less per 100 g (equivalent to 1 g of protein per 100 g) of dry product. Fruit and vegetables (excluding potatoes) containing less than 75 mg of phenylalanine per 100 g of food product should not adversely aff ect blood phenylalanine control and can be included without restriction in the diet. 60 The optimal amount of tyrosine provided in a low phenylalanine diet is unknown, but additional supplementation in excess of amounts provided by aminoacid supplements is not associated with a benefi t. 61 At present, no statement can be given regarding daily practice with reference to supplementation of large neutral aminoacids treatment (fi gure 2) or the use of glycomacropeptide because of insuffi cient evidence.
As illness and fever cause increased catabolism and higher blood phenylalanine concentrations, aminoacid supplements and energy requirements should be met during infection. Antipyretics or analgesics, such as paracetamol and ibuprofen, should be considered to control temperature and improve appetite.
Aspartame (E951) is an intense sweetener composed of 50% phenylalanine, 62, 63 and needs to be avoided in patients with PKU. In neotame, a similar artifi cial sweetener to aspartame, phenylalanine content is comparable but bioavailability is largely reduced.
64 Some medications contain aspartame (such as antibiotics), and short treatment courses might need to be given if no alternatives are readily available.
Patients with PKU, especially with a higher residual PAH activity, might respond to BH4 administration with a signifi cant increase in phenylalanine tolerance, or decrease in blood phenylalanine concentrations, or both. [65] [66] [67] All patients warrant testing for BH4 responsiveness either by genotyping or BH4 loading. 68 According to the group's consensus, in any patient without two known null mutations for PKU or two known BH4 responsive mutations, a 48 h BH4 loading test should be done by analysing the blood phenylalanine concentrations before and after a single daily dose (20 mg/kg per day) on two consecutive days. 68 In the neonatal period, to avoid delays in dietary treatment, a 24 h instead of 48 h BH4 loading test is advised before starting the diet. Treatment with BH4 should only be prescribed in cases of proven long-term BH4 responsiveness, defi ned as an increase in the amount of natural protein of 100% or more or improved biochemical control (phenylalanine >75% in target range) and proven by a trial (of up to 6 months) of treatment with BH4. The treatment trial starts at 10-20 mg of BH4 per kg bodyweight and natural protein intake is increased (with the advice of a dietician), the BH4 dose is adjusted, and the aminoacid supplements are decreased accordingly, while blood phenylalanine concentrations are still maintained in the target range. BH4 treatment should be stopped if blood phenylalanine concentrations are consistently above the upper target range, with a lack of response to an increase in BH4 dose. If nutritional status deteriorates (eg, development of obesity or nutritional defi ciencies), discontinuation of BH4 treatment should be discussed. BH4 treatment can be given during pregnancy, but only if women are known to be BH4 responders and dietary treatment alone is unsuccessful.
Follow-up and adherence
Treatment and follow-up of patients should be done in specialised metabolic centres, with at least an experienced metabolic physician and dietician for both children and adults, and a specialised metabolic laboratory. Establishing adult metabolic teams and centres to care for and monitor older patients with PKU is important. Ideally, these teams will be led by an adult metabolic disease physician who can coordinate care and liaise with diff erent specialties as necessary. Access to a neuro psychologist, or psychologist, and a social worker is strongly advised, but this advice is on the basis of clinical rather than evidence-based practice.
Follow-up includes home blood sampling and outpatient visits, the frequency of both being largely dependent on age (table 2) . Various life events, such as change of school, starting work, and living independently, as well as adherence issues (eg, during adolescence) might necessitate a higher frequency of blood phenylalanine testing or visits. The transition process not only includes the transition of patients from paediatric to adult care, but also the transition of the responsibility for treatment from parents to the patient. The pathway to greater autonomy generally starts at around 12 years with progression to adult services from the age of 16 years.
Outpatient visits include taking a medical and dietary history, collecting anthropometric data, such as body mass index, undertaking a physical and neurological examination, especially observing for clinical signs of phenylalanine toxicity and nutrient (including phenylalanine) defi ciency, 69, 70 and discussing issues of treatment and outcome (such as neurological and psychiatric issues, behaviour, and mood). Table 2 lists the additional investigations necessary, and these focus on potential nutritional defi ciencies (especially iron and vitamin B 12 ), [71] [72] [73] [74] neurocognitive measures, and bone mineral density. Clinical symptoms of nutrient defi ciency are rare and are mostly described because of vitamin B 12 defi ciency (if micronutrient supplemen tation, which is usually added to aminoacid supplements, is stopped or partially taken, alongside a meat-free diet). 73, 74 The incidence of osteopenia and osteoporosis in PKU is somewhat higher than in the general population, but only one study indicated that increased risk of fractures exists. 5, 75, 76 Follow-up is advised with dual-energy x-ray absorptiometry scanning once during late adolescence. If normal, a repeat scan is unnecessary. If abnormal, repetition with or without a change of treatment should follow after 1 year. Additionally, micronutrient defi ciencies (selenium, zinc, coenzyme Q10, and Review L-carnitine) have been linked to oxidative stress in PKU, 77 and oxidative stress is associated with poor metabolic control. 44 However, because of the lack of clinical symptoms associated with oxidative stress, and the absence of increased oxidative stress with adequate metabolic control, we do not propose routine biochemical monitoring of oxidative stress.
Routine neurocognitive assessments should be done at ages 12 years and 18 years in all patients, since blood phenylalanine treatment targets and life-phase changes occur at these ages (including change of school, living situation, starting work, and becoming an adult). We also advise measurement of quality of life and discussion of psychosocial functioning during clinic visits with PKU-specifi c health-related quality of life instruments. 30, 31 To achieve long-term adherence, changing the attitude and motivation of the patient might be more eff ective than improving knowledge. 78 Regular professional health support might be needed throughout life to encourage normal, healthy feeding behaviours, with a positive acceptance of a low phenylalanine diet. As health-care providers have a legal obligation to protect and care for each child in their care, the following considerations are proposed when a child (<12 years of age) is in poor metabolic control. When more than 50% of the phenylalanine concentrations are out of the target range during a period of 6 months (approximately 13 measurements per year), health-care providers should consider increased frequency of blood phenylalanine monitoring and outpatient visits, and re-education, plus psychology consultation or social worker interventions, and hospital admission. When around 100% of measured blood phenylalanine concentrations are out of the target range during a period of 6 months and other signs of failure of adherence; safety issues; or lack of cooperation, clinic non- Review attendance, or unresolved issues outside PKU, are also apparent, health-care providers should consider consultation with social services and child safeguarding measures. These proposals are based on the Delphi consensus method and are suggested in order to improve the outcome of patients from families who are resistant to routine advice and commonly fail to engage successfully with health professionals.
Special conditions
Within treatment for PKU, some specifi c conditions require a very specifi c treatment strategy. These groups include maternal PKU and late diagnosed or untreated PKU. Treatment for women with PKU also aims to prevent fetal eff ects of high maternal phenylalanine concentrations, called maternal PKU syndrome. 79 Blood phenylalanine concentrations should ideally be kept between 120 μmol/L and 360 μmol/L from preconception onwards. [80] [81] [82] [83] [84] Maintaining these concentrations necessitates continuous education throughout preadolescence, adolescence, and adulthood. 85 Contraceptive strategies should only be discontinued after stable phenylalanine concentrations within the target range have been achieved for at least 2 weeks, thus preventing sustained phenylalanine concentrations above or below the target range. 86 phenylalanine intake must immediately be increased by 50-100 mg per day when blood phenylalanine is 120 μmol/L or less at anytime during pregnancy. However, no treatment is necessary if untreated blood phenylalanine concentrations are less than 360 μmol/L. [87] [88] [89] Stable weight gain during pregnancy improves outcome, 90, 91 and energy intake should be monitored to ensure it is adequate but not excessive.
Referral to a fertility centre should be considered for patients with well controlled phenylalanine concentrations who do not conceive within 6 months. Women with an unplanned pregnancy should be seen within 24 h to initiate immediate dietary treatment. Treatment will require intensive intervention-eg, consider the use of the support of a home "Resource Mother" 45, 92 (available in the USA) or even hospital admission. 93 Treatment might be diffi cult because of nausea, which can necessitate dietary adjustments such as small and frequent low protein meals and snacks, 94 tube feeding, safe antiemetic therapy, and acid-reducing medications.
Blood phenylalanine concentration should be checked at least once weekly before pregnancy and at least twice Review weekly during pregnancy. This check requires a rapid laboratory turnaround time. High blood phenylalanine concentrations above target range (120-360 μmol/L) imply a high-risk pregnancy, necessitating the need for a fetal ultrasound at 18-22 weeks of pregnancy with screening for organ development (depending on the country, as for some countries this scan is an additional scan). Aminoacid supplements usually supply suffi cient tyrosine (intake should be at least 6 g per day). We advise 400 μg per day of folic acid preconceptually and during the fi rst 12 weeks of pregnancy, which corresponds with general antenatal recommendations.
We encourage breastfeeding and do not consider there to be contraindications for breastfeeding in maternal PKU, but clinical experience would suggest that the provision of breast feeding to an infant with PKU whose mother also has PKU requires careful monitoring with regard to the phenylalanine concentrations both in the mother and the infant.
Patients with PKU who are diagnosed late or patients with untreated PKU, especially because of newborn screening failures or lack of newborn screening or treatment (eg, immigrants), also need special consideration. [95] [96] [97] Patients with PKU who are diagnosed late can improve their IQ with treatment, [97] [98] [99] and improvements in seizures and behaviour can occur in patients with untreated PKU. 99 Therefore, regardless of age, we advise the identifi cation of these patients. Treatment for patients with a late diagnosis of PKU should always be considered, whereas in patients with untreated PKU, introduction of treatment is on an individual basis. If treatment is started, a treatment trial of 6 months should be given before the outcomes are assessed (including motor function [less tremors or spasticity] and behaviour [less restless and irritable, more alert or responsive, and less aggressive with decreased frequency and severity of self-injury behaviours]), but further data are required to give clear recommendations for the care of late diagnosed or untreated PKU.
Conclusion and future directions
To set a standard of care for all patients with PKU in Europe, we have developed this fi rst set of European guidelines for the diagnosis and treatment on the basis of the highest quality of available evidence. We have identifi ed knowledge gaps that require further research to direct better care for the future.
Optimisation of all current treatment strategies is essential, with a focus on adult and elderly patients and a defi nition of their diffi culties and any explanatory pathophysiological mechanisms. Such future treatment strategies might target the blood phenylalanine concentrations through the use of phenylalanine ammonia-lyase modifi ed with polyethylene glycol, new chaperones, and gene treatment. 100 Other treatments might directly aff ect cerebral metabolism, such as the use of large neutral aminoacids. Both glycomacropeptide and large neutral aminoacids are already being used in some countries but require further proof of safety and effi cacy. 101, 102 We also need to improve the quality of care delivered by some PKU centres, particularly in lowincome and middle-income countries, to achieve acceptable care for all patients with PKU in Europe. 8 To facilitate attainment of these objectives, the ESPKU and the development of European Reference Networks for PKU are important. Especially for rare diseases, an international consortia to investigate outcomes in relation to treatment strategies would be very useful. The European Reference Network for metabolic diseases, including PKU, is an important international consortium that can facilitate studying outcomes associated with varying treatments options and target phenylalanine concentrations in diff erent age ranges.
The availability of a device for home monitoring might further optimise outcomes, 103 as a shorter turnaround time to attain blood phenylalanine concentrations could help patients improve phenylalanine control.
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